Century Therapeutics (IPSC) Stock Analysis: AI Score & Alternative Data
IPSC alt-data: headcount climbing, job postings lagging
Is Century Therapeutics a buy right now? The alternative data says hold. This IPSC stock analysis is built on the 25+ alternative data signals AltIndex tracks on Century Therapeutics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 49/100: a Hold. The stock trades at $1.48 with a $277M market cap.
The bullish side of the 90-day ledger: headcount (according to LinkedIn) up 10.0% to 121 employees. The drag: job postings down 50.0% to 2 open roles, and web traffic down 13.1% to 6K monthly visits. That tension is what keeps the score mid-range.
IPSC’s broader alt-data profile also covers sentiment (100/100). Every signal links to its own page with full history, the IPSC technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on IPSC is just below.
Century Therapeutics AI Stock Analysis
Century Therapeutics, a biotechnology firm, focuses on the development of genetically engineered immune cell therapies for cancer. By leveraging state-of-the-art technology platforms, the company aims to create transformative treatment options.
Analysis generated October 1, 2026.
Recent Century Therapeutics Stock Alerts
|
Century Therapeutics | October 2 Price is down by -6.2% in the last 24h. |
|
Century Therapeutics | October 1 Price is down by -6.4% in the last 24h. |
|
Century Therapeutics | September 23 Price is down by -6.4% in the last 24h. |
|
Century Therapeutics | August 28 Price is down by -6.5% in the last 24h. |
Century Therapeutics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 6K | 13.1% | |
| Job Posts | 2 | 50.0% | |
| LinkedIn Employees | 121 | 10.0% | |
| Wikipedia Views | 286 | 24.3% | |
| Sentiment | 100 | 0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 5 | 66.7% | |
| Stocktwits Mentions | 6 | N/A | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 710 | 1.1% | |
| 4chan Mentions | 0 | N/A |
About Century Therapeutics (IPSC)
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
| Price | $1.48 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $277M |
| Year Range | $0 – $3 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Century Therapeutics News
View more →
Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific CongressesJuly 14 - Yahoo Entertainment |
|
Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026July 9 - GlobeNewswire |
|
Century Therapeutics Reports First Quarter Financial Results and Business UpdatesMay 13 - GlobeNewswire |
|
Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific SessionsApril 30 - GlobeNewswire |
|
 |
Century Therapeutics: A Very Promising Contender In The Type I Diabetes Mellitus Functional Cure RaceFebruary 8 - SeekingAlpha |
See Century Therapeutics’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for IPSC, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREECentury Therapeutics Earnings & Financial Performance
View all earnings →Century Therapeutics Insider Trading Activity
View all →| Carr Douglas filed to sell 502,907 shares at $0.0. Sep 14 '26 |
| Russotti Gregory filed to sell 509,198 shares at $0.0. Sep 14 '26 |
| Carr Douglas filed to sell 504,565 shares at $0.0. Sep 8 '26 |
| Russotti Gregory filed to sell 511,785 shares at $0.0. Sep 8 '26 |
| Carr Douglas filed to sell 504,819 shares at $0.0. Aug 3 '26 |
Century Therapeutics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Century Therapeutics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Inhibikase TherapeuticsIKT |
$2.00 0.0% | $279M | 47 |
 |
Vanda PharmaceuticalsVNDA |
$4.58 1.1% | $280M | 53 |
 |
X4 PharmaceuticalsXFOR |
$2.90 2.5% | $281M | 46 |
 |
Eyepoint PharmaceuticalsEYPT |
$3.15 3.1% | $272M | 36 |
 |
Abeona TherapeuticsABEO |
$5.11 1.6% | $288M | 44 |
Explore Century Therapeutics Data
Frequently Asked Questions: Century Therapeutics (IPSC)
Century Therapeutics has an AltIndex AI Score of 49/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
49/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Century Therapeutics (IPSC) stock is $1.48 with a market cap of $277M.
As of today, Century Therapeutics’s PE (Price to Earnings) ratio is —.
View the latest Century Therapeutics insider transactions to see recent buying and selling activity by company executives and directors.
Check the Century Therapeutics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The IPSC stock price chart above shows Century Therapeutics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Century Therapeutics technical analysis for RSI, moving averages, and more.
See the stocks similar to Century Therapeutics section on this page for companies in the same industry ranked by market cap and AI Score.
